These new changes facilitate use of specific PSMA response criteria such as PSMA PET Progression criteria (PPP) which focuses on a single lesion or Response Evaluation Criteria in PSMA-PET/CT (RECIP) which mostly focuses on total tumor volume in patients with extensive disease [62]. The gene discussed is FOLH1; the disease is neoplasm.